The results we present here for purified memory-phenotype CD4+ T cells and for effector-memory Th17 cells derived from obstructed kidney indicate suppression of IL-17A secretion comparable to that of naïve CD4+ T cells. In the case of memory-phenotype CD4+ T cells activated in vitro under Th17-skewing conditions, MSC contact was also associated with inhibition of proliferation and of CD25 up-regulation. These results this website are in-line with the in vitro and in vivo findings of Rafei et al. for MSC effects on MOG-specific Th17 cells in mouse EAE 14. In addition, MSC-mediated suppression
of Th17 responses has been reported for antigen-specific Th17 cells in rat EAE and autoimmune myasthenia gravis and in established autoimmune diabetes mellitus in NOD mice 32, 33. Interestingly, however, evidence for enhancement of Th17 differentiation and IL-17A production
by MSCs and fibroblasts has also been presented in a small number of studies 34, 35. The reported results suggested that MSC production of IL-6 as well as stimulation of IL-1 and/or IL-23 secretion by APCs were responsible for the observations 34, 35. In our own experiments, we have observed that administration of a non-selective COX inhibitor in MSC/Th17 co-cultures is associated with enhancement of IL-17A secretion compared with control Th17 cultures (Fig. 5A and our unpublished observation). We have also confirmed production of IL-6 and TGF-β1 by MSCs co-cultured with activated T cells (our unpublished observation). Thus, it is important to consider that MSC Selleck FK506 next inhibition of Th17 cell differentiation and activation, while potent, is conditional, being dependent upon opportune MSC/T-cell contact and upon inducible mechanisms which, when absent or subject to blockade, may unmask a paradoxical
capacity for enhancement of Th17 activity. Furthermore, in the case of naturally occurring Th17 cells from obstructed kidney (or other sites of inflammation and autoimmunity), additional experimental work will be required to distinguish between direct and indirect MSC effects on this T-cell effector phenotype. From a mechanistic perspective, we provide compelling evidence that the induced production of PGE2 by MSCs in direct contact with CD4+ T cells undergoing activation was primarily responsible for suppressive effects on naïve- and memory-phenotype Th17 cells in vitro as well as on in vivo-derived effector-memory Th17 cells. This is consistent with the report of Ghannam et al. in which indomethacin reversed MSC-mediated suppression of Th17 differentiation from human naïve, cord-blood CD4+ T cells as well as IL-17A production by Th17 clones 9. By utilizing FACS to re-purify MSCs, we convincingly demonstrate significant up-regulation of COX-2 and production of PGE2 by these cells within 12–24 h of placement in Th17-skewing cultures.